Faculty Profiles - IWASAKI Yoshiaki

MISC - IWASAKI Yoshiaki

Division display 161 - 180 of about 510 ／ All the affair displays >>

メンタルヘルス出前講義がもたらす受診行動の変容

清水幸登, 仁科舞子, 河原宏子, 兒山志保美, 大西勝, 岡香織, 黒木清美, 内藤恵子, 古賀光, 岩﨑良章, 小倉俊郎

第42回中国・四国大学保健管理研究集会報告書 42 110 - 113 2012

肝疾患治療薬（インターフェロン製剤、抗肝炎ウイルス薬）

岩﨑良章, 池田房雄, 山本和秀

日本臨床 70 ( 臨時増刊6 ) 272 - 278 2012

大学新入生における血清総コレステロール値の過去5年間の推移とLDL-コレステロール検査の導入

岩﨑良章, 今井あゆみ, 岡香織, 黒木清美, 内藤恵子, 小林むつみ, 古賀光, 河原宏子, 清水幸登, 大西勝, 小倉俊郎

第42回中国・四国大学保健管理研究集会報告書 42 85 - 88 2012

医療系地区保健管理センター開設１０年後の現状と課題

黒木清美, 大西勝, 岩﨑良章, 内藤恵子, 中西順子, 兒山志保美, 岡香織, 森田知子, 古賀光, 清水幸登, 小倉俊郎

第42回中国・四国大学保健管理研究集会報告書 42 93 - 95 2012

岡山大学における雇用障がい者の就業支援への工夫－就労前面談の効用とその注意

清水幸登, 仁科舞子, 兒山志保美, 大西勝, 河原宏子, 黒木清美, 内藤恵子, 絹見佳子, 古賀光, 岩﨑良章, 小倉俊郎

CAMPUS HEALTH 49 ( 1 ) 344 - 346 2012

メンタルヘルス出前講義がもたらす受診行動の変容

清水幸登, 仁科舞子, 河原宏子, 兒山志保美, 大西勝, 岡香織, 黒木清美, 内藤恵子, 古賀光, 岩﨑良章, 小倉俊郎

第42回中国・四国大学保健管理研究集会報告書 85 - 88 2012

Massive bleeding from acute multiple nonspecific ulcer of the small intestine after R-CHOP with a diffuse large B-cell lymphoma: A rare case report

Kazuya Kato, Atsushi Nagase, Kazuhiko Onodera, Minoru Matsuda, Yurina Kato, Kimitaka Kato, Takako Kawakami, Mineko Higuchi, Yoshiaki Iwasaki, Masahiko Taniguchi, Hiroyuki Furukawa

American Journal of Case Reports 12 198 - 202 2011.12

Language：English Publishing type：Book review, literature introduction, etc. Publisher：Medical Science International

Background: The small intestine between the second part of the duodenum and ileocecal valves is an uncommon site for hemorrhage. Ulcers of the small intestine are rare and in most cases are caused by infections, inflammatory bowel diseases, malignancies or drugs. Ulcers of the small intestine are sometimes associated with massive, life-threatening hemorrhage and are difficult to diagnose. Case Report: We report a case of acute, massive bleeding from multiple small-bowel ulcers in a 78-year-old woman with malignant lymphoma (diffuse large B-cell lymphoma) after R-CHOP (cyclophosphamide, vincristine, doxorubicine, prednisolone and rituximab) therapy. Conclusions: The current report describes a rare case of acute, multiple, nonspecific small intestine ulcers associated with massive gastrointestinal bleeding and presents a review of the literature. © The American Journal of Case Reports.

DOI： 10.12659/AJCR.882207

Scopus

researchmap

Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis

Tetsuya Yasunaka, Akinobu Takaki, Takahito Yagi, Yoshiaki Iwasaki, Hiroshi Sadamori, Kazuko Koike, Satoshi Hirohata, Masashi Tatsukawa, Daisuke Kawai, Hidenori Shiraha, Yasuhiro Miyake, Fusao Ikeda, Haruhiko Kobashi, Hiroaki Matsuda, Susumu Shinoura, Ryuichi Yoshida, Daisuke Satoh, Masashi Utsumi, Teppei Onishi, Kazuhide Yamamoto

HEPATOLOGY INTERNATIONAL 5 ( 4 ) 918 - 926 2011.12

Language：English Publisher：SPRINGER

Purpose The combination of hepatitis B immunoglobulin (HBIg) and nucleos(t)ide analogues has been accepted as the best treatment to control hepatitis B recurrence after orthotopic liver transplantation (OLT). However, the optimal dose of HBIg remains unclear. We have previously reported that high-dose HBIg in the early period followed by low-dose HBIg with nucleos(t)ide analogues offers reliable and cost-effective control of hepatitis B recurrence. The aim of this study was to investigate intrahepatic hepatitis B virus (HBV) reinfection status with our clinically successful protocol.
Methods We quantified levels of intrahepatic HBV covalently closed circular (ccc) deoxyribonucleic acid (DNA) and serum hepatitis B core-related antigen (HBcrAg), a new serological marker that can estimate intrahepatic cccDNA levels. Nucleos(t)ide analogues were administered in all cases.
Results No patients showed recurrence of hepatitis B surface antigen (HBsAg) or HBV-DNA. However, HBV, cccDNA, and HBcrAg were positive in 57% and 48% of patients after OLT, respectively. Pre-OLT serum HBV-DNA and HBcrAg levels correlated linearly with post-OLT cccDNA levels (r = 0.534, P < 0.05, and r = 0.634, P < 0.05, respectively). High serum HBV-DNA and HBcrAg levels, particularly with > 3 log(10) copies/mL and > 4 log(10) IU/mL, respectively, at the time of OLT, were associated with high levels of post-OLT cccDNA. Even with our successful protocol, nearly half of patients showed HBV reinfection.
Conclusions Patients with high serum HBV-DNA and HBcrAg levels before OLT (particularly > 3 log(10) copies/mL and > 4 log(10) IU/mL, respectively) should be followed with care for HBV recurrence.

DOI： 10.1007/s12072-011-9265-z

Web of Science

researchmap

C型慢性肝炎に対するインターフェロン単独長期投与における治療反応性と肝発癌の検討

岩崎良章, 高口浩一, 下村宏之, 下江俊成, 藤岡真一, 橋本訓招, 池田房雄, 三宅康広, 高木章乃夫, 山本和秀

肝臓 52 ( Suppl.3 ) A921 - A921 2011.11

C型慢性肝炎に対するインターフェロン(IFN)療法における予後予測因子としてのQuality of life(QOL)スコアの解析

松下浩志, 池田房雄, 岩崎良章, 竹内康人, 森藤由記, 安中哲也, 三宅康広, 高木章乃夫, 山本和秀

肝臓 52 ( Suppl.3 ) A920 - A920 2011.11

脂肪肝はメタボリックシンドローム関連疾患発症を予知する可能性がある

守屋昭男, 岩崎良章, 大口創平, 谷口英明, 池田房雄, 宮武宏和, 安東正晴, 山本和秀

肝臓 52 ( Suppl.3 ) A848 - A848 2011.11

Hepatitis B virus core promoter mutations G1613A and C1653T are significantly associated with hepatocellular carcinoma in genotype C HBV-infected patients

Masashi Tatsukawa, Akinobu Takaki, Hidenori Shiraha, Kazuko Koike, Yoshiaki Iwasaki, Haruhiko Kobashi, Shin-Ichi Fujioka, Kohsaku Sakaguchi, Kazuhide Yamamoto

BMC CANCER 11 458 2011.10

Language：English Publisher：BIOMED CENTRAL LTD

Background: Hepatitis B virus (HBV) is a major cause of hepatocarcinogenesis. To identify mutations relevant to hepatocellular carcinoma (HCC) development, we compared the full genome sequences of HBV from the sera of patients with and without HCC.
Methods: We compared the full genome sequences of HBV isolates from 37 HCC patients (HCC group 1) and 38 patients without HCC (non-HCC group 1). We also investigated part of the core promoter region sequences from 40 HCC patients (HCC group 2) and 68 patients without HCC. Of the 68 patients who initially did not have HCC, 52 patients remained HCC-free during the follow-up period (non-HCC group 2), and 16 patients eventually developed HCC (pre-HCC group 2). Serum samples collected from patients were subjected to PCR, and the HBV DNA was directly sequenced.
Results: All patients had genotype C. A comparison of the nucleotide sequences of the HBV genome between HCC group 1 and non-HCC group 1 revealed that the prevalence of G1613A and C1653T mutations in the core promoter region was significantly higher in the HCC group. These mutations tended to occur simultaneously in HCC patients. Multivariate analysis with group 2 revealed that the presence of HCC was associated with aging and the double mutation. Future emergence of HCC was associated with aging and the presence of a single G1613A mutation.
Conclusions: G1613A and C1653T double mutations were frequently found in patients with HCC. A single G1613A mutation was associated with future emergence of HCC. These mutations may serve as useful markers in predicting HCC development.

DOI： 10.1186/1471-2407-11-458

Web of Science

researchmap

岡山大学における雇用障がい者の就業支援への工夫就労前面談の効用とその注意点

清水幸登, 仁科舞子, 兒山志保美, 大西勝, 河原宏子, 安東節子, 黒木清美, 内藤恵子, 絹見佳子, 古賀光, 岩崎良章, 小倉俊郎

CAMPUS HEALTH 48 ( 3 ) 86 - 86 2011.10

病院実習前の医療系学生に対するクォンティフェロン検査 5年間の検討

岩崎良章, 古賀光, 絹見佳子, 内藤恵子, 黒木清美, 中西順子, 森田知子, 今井あゆみ, 小林むつみ, 大西勝, 清水幸登, 小倉俊郎

CAMPUS HEALTH 48 ( 3 ) 66 - 66 2011.10

受動喫煙防止対策としての職員健診時アンケート調査と尿中コチニン測定

絹見佳子, 古賀光, 内藤恵子, 黒木清美, 岩崎良章, 清水幸登, 大西勝, 小倉俊郎

CAMPUS HEALTH 48 ( 3 ) 90 - 90 2011.10

Roles of alcohol consumption in fatty liver in Japanese women

A. Moriya, Y. Iwasaki, S. Ohguchi, E. Kayashima, T. Mitsumune, H. Miyatake, M. Ando, F. Ikeda, K. Yamamoto

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 26 172 - 172 2011.10

THE RELATIONSHIPS OF PNPLA3 RS738409 POLYMORPHISM WITH THE ETIOLOGY OF LIVER DISEASES AND THE INCIDENCE OF HEPATOCELLULAR CARCINOMA

Yasuto Takeuchi, Fusao Ikeda, Yuki Moritou, Tetsuya Yasunaka, Yasuhiro Miyake, Akinobu Takaki, Yoshiaki Iwasaki, Kazuhide Yamamoto

HEPATOLOGY 54 1425A - 1425A 2011.10

HAVING FATTY LIVER MAY PREDICT THE DEVELOPMENT OF METABOLIC SYNDROME-RELATED FACTORS

Akio Moriya, Yoshiaki Iwasaki, Souhei Ohguchi, Eizo Kayashima, Tadahiko Mitsumune, Hideaki Taniguchi, Fusao Ikeda, Kazuhide Yamamoto

HEPATOLOGY 54 1119A - 1119A 2011.10

C型慢性肝炎に対するペグインターフェロンα+リバビリン併用療法の期間延長投与による治療効果改善におけるIL28B、ITPA遺伝子多型の影響

池田房雄, 岩崎良章, 森藤由記, 安中哲也, 竹内康人, 三宅康広, 高木章乃夫, 高口浩一, 荒木康之, 山本和秀

日本消化器病学会雑誌 108 ( 臨増大会 ) A933 - A933 2011.9

Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid

Yasuto Takeuchi, Fusao Ikeda, Shin-ichi Fujioka, Toshiyuki Takaki, Toshiya Osawa, Tetsuya Yasunaka, Yasuhiro Miyake, Akinobu Takaki, Yoshiaki Iwasaki, Haruhiko Kobashi, Kazuhide Yamamoto, Tatsuya Itoshima

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY 26 ( 9 ) 1395 - 1401 2011.9

Language：English Publisher：WILEY-BLACKWELL

Background and Aim: Ursodeoxycholic acid (UDCA) has been widely used in the treatment of patients with primary biliary cirrhosis (PBC). However, some patients are refractory to UDCA. The aim of this study is to clarify the additive improvement induced by bezafibrate in patients refractory to UDCA.
Methods: This study was a prospective analysis of 37 consecutive PBC patients. All patients were treated first for 6 months with UDCA, and then with bezafibrate, if their alkaline phosphatase (ALP) levels did not decrease more than 40% or within the normal range after 6 months' treatment with UDCA. Clinical parameters were monitored for the subsequent 24 months.
Result: Twenty-two patients (59%) achieved improvement of ALP levels after the treatment with UDCA. Those patients (Group A) had significantly lower levels of ALP at diagnosis than those with abnormal ALP levels after 6 months' treatment with UDCA (Group B; P = 0.020). They continued UDCA monotherapy, and maintained normal ALP levels at subsequent follow ups. However, immunoglobulin M (IgM) levels remained abnormal in eight patients, whose IgM levels at the time of diagnosis were significantly higher than those whose IgM were normalized after 6 months' treatment with UDCA (P = 0.026). Those in Group B were treated additionally with bezafibrate, and 12 patients (80%) achieved normalALP and IgM levels within 12 months of commencement of therapy.
Conclusion: Higher ALP level at diagnosis is one of the predictors for UDCA failure. Combination treatment of bezafibrate in addition to UDCA may be an effective treatment for PBC patients refractory to UDCA.

DOI： 10.1111/j.1440-1746.2011.06737.x

Web of Science

researchmap

　 PREV - NEXT 　

< IWASAKI Yoshiaki >

MISC - IWASAKI Yoshiaki